JP2008539182A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008539182A5 JP2008539182A5 JP2008508138A JP2008508138A JP2008539182A5 JP 2008539182 A5 JP2008539182 A5 JP 2008539182A5 JP 2008508138 A JP2008508138 A JP 2008508138A JP 2008508138 A JP2008508138 A JP 2008508138A JP 2008539182 A5 JP2008539182 A5 JP 2008539182A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- protein
- immunogenic fragment
- vaccine according
- excluded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccines Drugs 0.000 claims 44
- 108090000623 proteins and genes Proteins 0.000 claims 22
- 102000004169 proteins and genes Human genes 0.000 claims 22
- 230000002163 immunogen Effects 0.000 claims 20
- 241000341655 Human papillomavirus type 16 Species 0.000 claims 8
- 239000002671 adjuvant Substances 0.000 claims 7
- 230000000240 adjuvant Effects 0.000 claims 7
- 201000009910 diseases by infectious agent Diseases 0.000 claims 7
- 230000002246 oncogenic Effects 0.000 claims 6
- 231100000590 oncogenic Toxicity 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 102000005857 Human papillomavirus type 18 L1 protein Human genes 0.000 claims 3
- 101000162572 Major capsid protein L1 Proteins 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical group [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 2
- 230000002380 cytological Effects 0.000 claims 2
- 101710004056 CWINV1 Proteins 0.000 claims 1
- 101710004059 CWINV3 Proteins 0.000 claims 1
- 108060008088 TBCC Proteins 0.000 claims 1
- 101710015135 TPS27 Proteins 0.000 claims 1
- 230000003902 lesions Effects 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000002085 persistent Effects 0.000 claims 1
Claims (31)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/114,301 US20050287161A1 (en) | 2002-12-20 | 2005-04-26 | Vaccine |
PCT/EP2005/006461 WO2005123125A1 (en) | 2004-06-16 | 2005-06-14 | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 |
US11/367,601 US7858098B2 (en) | 2002-12-20 | 2005-12-16 | Vaccine |
PCT/EP2006/003809 WO2006114273A2 (en) | 2005-04-26 | 2006-04-24 | Vaccine |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008539182A JP2008539182A (en) | 2008-11-13 |
JP2008539182A5 true JP2008539182A5 (en) | 2009-04-23 |
Family
ID=37199195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008508138A Pending JP2008539182A (en) | 2005-04-26 | 2006-04-24 | vaccine |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1879614A2 (en) |
JP (1) | JP2008539182A (en) |
KR (1) | KR20080005583A (en) |
AR (1) | AR053715A1 (en) |
AU (1) | AU2006239471A1 (en) |
CA (1) | CA2606206A1 (en) |
EA (1) | EA013325B1 (en) |
MX (1) | MX2007013475A (en) |
NO (1) | NO20075185L (en) |
SG (1) | SG159529A1 (en) |
UY (1) | UY29499A1 (en) |
WO (1) | WO2006114273A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102215861B (en) * | 2009-06-19 | 2014-10-08 | 艾金株式会社 | Vaccine for cervical cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
US6908613B2 (en) * | 2000-06-21 | 2005-06-21 | Medimmune, Inc. | Chimeric human papillomavirus (HPV) L1 molecules and uses therefor |
GB0206360D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
EP1572233B1 (en) * | 2002-12-20 | 2011-03-30 | GlaxoSmithKline Biologicals s.a. | Use of HPV16 and HPV18 as vaccine against one or more of oncogenic HPV type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 |
MXPA06014515A (en) * | 2004-06-16 | 2007-03-23 | Glaxosmithkline Biolog Sa | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52. |
-
2006
- 2006-04-24 SG SG201000826-6A patent/SG159529A1/en unknown
- 2006-04-24 AR ARP060101618A patent/AR053715A1/en not_active Application Discontinuation
- 2006-04-24 EA EA200702077A patent/EA013325B1/en unknown
- 2006-04-24 AU AU2006239471A patent/AU2006239471A1/en not_active Abandoned
- 2006-04-24 EP EP06753410A patent/EP1879614A2/en not_active Ceased
- 2006-04-24 MX MX2007013475A patent/MX2007013475A/en unknown
- 2006-04-24 WO PCT/EP2006/003809 patent/WO2006114273A2/en active Application Filing
- 2006-04-24 CA CA002606206A patent/CA2606206A1/en not_active Abandoned
- 2006-04-24 JP JP2008508138A patent/JP2008539182A/en active Pending
- 2006-04-24 KR KR1020077027492A patent/KR20080005583A/en not_active Application Discontinuation
- 2006-04-26 UY UY29499A patent/UY29499A1/en not_active Application Discontinuation
-
2007
- 2007-10-11 NO NO20075185A patent/NO20075185L/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1410805B1 (en) | Vaccine against HPV | |
Gambhira et al. | Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2 | |
JP2006512413A5 (en) | ||
US9149503B2 (en) | Papillomavirus-like particles (VLP) as broad spectrum human papillomavirus (HPV) vaccines | |
RU2014102200A (en) | VACCINE COMPOSITIONS AGAINST HUMAN PAPILLOMA VIRUS (HPV), CONTAINING ALUMINUM ADJUVANT AND METHODS FOR PRODUCING THEM | |
CA2543928A1 (en) | Optimized expression of hpv 58 l1 in yeast | |
WO2002090382A3 (en) | Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof | |
CA2539168A1 (en) | Optimized expression of hpv 45 l1 in yeast | |
CA2519112A1 (en) | Optimized expression of hpv 31 l1 in yeast | |
CA2510457A1 (en) | Hpv-16 and -18 l1 vlp vaccine | |
Huber et al. | A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types | |
Panatto et al. | Human papillomavirus vaccine: State of the art and future perspectives | |
AU2005253723B2 (en) | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 | |
JP2008539182A5 (en) | ||
Roden et al. | The impact of preventive HPV vaccination | |
Webb et al. | Cervical cancer-causing human papillomaviruses have an alternative initiation site for the L1 protein | |
CN101116745B (en) | Human papilloma virus sample particle vaccines | |
US7858098B2 (en) | Vaccine | |
JP2013540421A5 (en) | ||
JP2002532434A5 (en) | ||
Grce et al. | Burden and prevention of HPV related diseases: Situation in Croatia | |
Hariharan et al. | Genotypes of the human papillomavirus: Relevance to Indian field trials of the vaccine | |
Buttà et al. | Concurrence and concordance of Human Papillomavirus in orogenital infection | |
張士泰 | The prevalence of VAIN, CIN, and related HPV genotypes in Japanese women with abnormal cytology | |
Bala et al. | CERVICAL CANCER: DISEASE AND ITS PATHOLOGY |